Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Allogene Therapeutics, Inc. (ALLO)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-05-18
   10-K10-K10-K10-K10-K8-K
Revenues        
Collaboration revenue - related party  0.238.5   151.9
            Collaboration revenue - related party growth  -99.4%     
Operating expenses:        
Research and development  256.4220.2193.0144.5151.9 
General and administrative  79.374.165.357.541.041.0
    Total operating expenses  335.7294.3258.2202.0192.8192.8
    Loss from operations  -335.4-255.8-258.2-202.0-192.8-192.8
            Operating margin  -138044.9%-664.6%    
   
Other income (expense), net:        
Interest and other income, net  4.61.79.2   
Other (expenses) income  -1.7-2.9-1.117.45.8 
    Total other income, net  2.8-4.18.034.4-18.8 
    Net loss  -332.6-257.0-250.2-184.6-211.5-211.5
   
Other comprehensive loss:        
    Net comprehensive loss  -340.0-259.8-251.1-183.8-211.2 
   
Net loss per share, basic (in dollars per share)  ($2.32)($1.89)($2.08)($1.83)($7.31)($7.31)
Net loss per share, diluted (in dollars per share)  ($2.32)($1.89)($2.08)($1.83)($7.31)($7.31)
   
Weighted-average number of shares used in computing net loss per share, basic  143.1135.8120.4101.128.928.9
Weighted-average number of shares used in computing net loss per share, diluted  143.1135.8120.4101.1  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy